MD Anderson, Ipsen advance new therapy with potential benefit for underserved lung and ovarian cancer patients
ABSTRACT: DDT01-03
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain...
Majority of patients responded in CAR T-cell trial for mantle cell lymphoma
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma...
Immunotherapy effective in metastatic prostate cancers with specific markers of immune activation
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients with...